Abstract / Summary
ObjectiveTo investigate the predictive value of the triglyceride-glucose(TyG) index at admission for new-onset atrial fibrillation after continuous renal replacement therapy(CRRT) in patients in the intensive care unit (ICU).MethodsA total of 171 ICU patients who received CRRT for≥24 h at Xuzhou Municipal Hospital from June 1, 2021 to December 31, 2024 were retrospectively included. According to whether atrial fibrillation occurred after CRRT, patients were divided into an atrial fibrillation group (29 cases) and a non-atrial fibrillation group (142 cases). Baseline characteristics were compared between the two groups. Restricted cubic splines (RCS), a multivariate logistic regression model, and the area under the curve (AUC) of the receiver operating characteristic curve were used to evaluate the predictive value of the TyG index for new-onset atrial fibrillation after CRRT in ICU patients.ResultsThere were significant differences between the two groups in age ([79.31±10.29] years vs. [61.68±18.45] years), proportion with coronary heart disease (20.69% vs 4.93%), proportion with diabetes (55.17% vs 27.46%), TyG index (10.00±1.19 vs 9.15±1.09), and serum potassium level ([4.93±1.06] mmol/L vs [4.53±0.89] mmol/L) (all P<0.05). RCS showed a linear relationship between the TyG index and new-onset atrial fibrillation after CRRT in ICU patients. The adjusted multivariate logistic regression model indicated that the TyG index was an important independent predictor of new-onset atrial fibrillation after CRRT in ICU patients(OR=3.36, 95%CI: 2.07-6.00) and had a certain predictive value for this outcome, with an AUC of 0.796(95%CI: 0.690-0.902).ConclusionThe TyG index is an independent risk factor for new-onset atrial fibrillation after CRRT in ICU patients.
Topics
Primary Source
Linchuang shenzangbing zazhi
Ask Prognia AI
Have questions about this review article?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.